NR4A1 and breast carcinoma: Despite the well-documented role as a tumour suppressor, in breast cancer, miR-375-3p is upregulated [16,27,28] and is highly expressed in hormone-receptor-positive breast tumours [29] and lymph-node-positive patients [29].